nirmatrelvir - dofaq.co
Effectiveness and safety of Sanhan Huashi granules versus nirmatrelvir–ritonavir in adult patients with COVID-19: A ...
ScienceDirect.com - 23 Apr 2024
Effectiveness and safety of Sanhan Huashi granules versus nirmatrelvir –ritonavir in adult patients with COVID-19: A ... ...
Nirmatrelvir fails to shorten COVID-19 symptoms in latest trial
News-Medical.Net - 08 Apr 2024
Nirmatrelvir fails to shorten COVID-19 symptoms in latest trial ...
Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation
Nature - 01 Nov 2023
Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation ...
COVID rebound common, does not differ after VV116 vs nirmatrelvir–ritonavir treatment | Latest news for Doctors ...
MIMS - 15 Apr 2024
COVID rebound common, does not differ after VV116 vs nirmatrelvir –ritonavir treatment | Latest news for Doctors ... ...
Expansion of patient groups eligible for Paxlovid treatment for COVID-19
Department of Health NI - 25 Apr 2024
Expansion of patient groups eligible for Paxlovid treatment for COVID-19 ...
WHO updates guidelines on treatments for COVID-19
World Health Organization (WHO) - 10 Nov 2023
WHO updates guidelines on treatments for COVID-19 ...
The effect of nirmatrelvir-ritonavir on hospital admissions and mortality from COVID-19
IDSA - 21 Dec 2023
The effect of nirmatrelvir -ritonavir on hospital admissions and mortality from COVID-19 ...
Paxlovid Doesn't Reduce Most Post-COVID Conditions
Medscape - 30 Oct 2023
Paxlovid Doesn't Reduce Most Post-COVID Conditions ...
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Nature - 16 Dec 2023
Optimal timing of nirmatrelvir /ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation ...
Exploring the dual role of nirmatrelvir and bisphosphonates in COVID-19 treatment and immunity
News-Medical.Net - 16 Nov 2023
Exploring the dual role of nirmatrelvir and bisphosphonates in COVID-19 treatment and immunity ...
COVID-19 rebound common following treatment with either VV116 or nirmatrelvir-ritonavir | Latest news for Doctors ...
MIMS - 20 Mar 2024
COVID-19 rebound common following treatment with either VV116 or nirmatrelvir -ritonavir | Latest news for Doctors ... ...
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir
Nature - 11 Sep 2023
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir ...
Nirmatrelvir treatment shows no link to reduced long-COVID risk, study reveals
News-Medical.Net - 08 Jan 2024
Nirmatrelvir treatment shows no link to reduced long-COVID risk, study reveals ...
Nirmatrelvir reduces the risk of long COVID | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
MIMS - 05 Mar 2024
Nirmatrelvir reduces the risk of long COVID | Latest news for Doctors, Nurses and Pharmacists | Pharmacy ...
Predictors of nirmatrelvir–ritonavir receipt among COVID-19 patients in a large US health system | Scientific Reports
Nature - 29 Mar 2024
Predictors of nirmatrelvir –ritonavir receipt among COVID-19 patients in a large US health system | Scientific Reports ...
One in five patients on Nirmatrelvir–Ritonavir experience virologic rebound, new observational study reveals
News-Medical.Net - 16 Nov 2023
One in five patients on Nirmatrelvir–Ritonavir experience virologic rebound, new observational study reveals ...
Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study | Scientific Reports
Nature - 11 Nov 2023
Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study | Scientific Reports ...
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a ...
Nature - 09 Feb 2024
Comparison of azvudine, molnupiravir, and nirmatrelvir /ritonavir in adult patients with mild-to-moderate COVID-19: a ... ...
In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
Nature - 04 Jul 2023
In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir ...